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A critical function of macrophages within the inﬂammatory milieu is the removal of dying
cells by a specialized phagocytic process called efferocytosis (“to carry to the grave”).
Through speciﬁc receptor engagement and induction of downstream signaling, efferocy-
tosing macrophages promote resolution of inﬂammation by (i) efﬁciently engulﬁng dying
cells, thus avoiding cellular disruption and release of inﬂammatory contents, and (ii) pro-
ducing anti-inﬂammatory mediators such as IL-10 andTGF-β that dampen pro-inﬂammatory
responses. Evidence suggests that plasticity in macrophage programming, in response
to changing environmental cues, modulates efferocytic capability. Essential to program-
ming for enhanced efferocytosis is activation of the nuclear receptors PPARγ, PPARδ, LXR,
and possibly RXRα. Additionally, a number of signals in the inﬂammatory milieu, including
those from dying cells themselves, can inﬂuence efferocytic efﬁcacy either by acting as
immediate inhibitors/enhancers or by altering macrophage programming for longer-term
effects. Importantly, sustained inﬂammatory programming of macrophages can lead to
defective apoptotic cell clearance and is associatedwith development of autoimmunity and
other chronic inﬂammatory disorders. This review summarizes the current knowledge of
the multiple factors that modulate macrophage efferocytic ability and highlights emerging
therapeutic targets with signiﬁcant potential for limiting chronic inﬂammation.
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INTRODUCTION
Efferocytosis, or engulfment of apoptotic cells by macrophages is
an essential process with roles in tissue homeostasis, embryologic
development, immunity, and resolution of inﬂammation, the lat-
ter, the focus of this review.Apoptotic cells exhibit surface changes,
especially exposure of the plasma membrane inner leaﬂet phos-
pholipid phosphatidylserine (PS) or its oxidized forms (Fadok
et al., 1992; Greenberg et al., 2006), that distinguish them from
viable cells and allow recognition by a multiplicity of macrophage
efferocytic receptors (Table 1). Other surface ligands on apoptotic
cells, e.g., calreticulin and deposited complement, are reviewed
elsewhere (Henson and Bratton, 2009). In many instances, factors
in plasma (or serum), often produced bymacrophages themselves,
are utilized as bridge molecules to couple apoptotic cells to the
macrophage receptors (Table 1). Engagement of efferocytic recep-
tors initiates signaling events modulated by two main complexes,
CrkII/ELMO/Dock180 (Gumienny et al., 2001) or ABCA1/GULP
(Kinchen et al., 2005), both resulting in activation of Rac1, which
initiates cytoskeletal rearrangement and subsequent engulfment.
Rac1 and RhoA, two small Rho GTPases, have opposing roles in
regulating efferocytosis; Rac1 enhances, while RhoA inhibits the
process (Leverrier and Ridley, 2001; Nakaya et al., 2006). Thus,
the relative balance between them plays a key role in determin-
ing macrophage efferocytic ability, and imbalance favoring active
RhoA can lead to defective clearance.
Macrophages subserve key roles during inﬂammation and
its resolution. As innate immune sentinels, resident tissue
macrophages detect and interpret signals indicating tissue injury
or pathogen inﬁltration and initiate responses through release of
cytokines and other mediators. Consequently, leukocyte recruit-
ment ensues, including blood monocytes that differentiate into
macrophages. Changing cues in the inﬂammatory milieu alter
macrophage programming and modulate various endocytic func-
tions. Phagocytosis andmacropinocytosis are essential for removal
of infectious agents, antigen presentation, and activation of
adaptive immune responses, while efferocytosis can help initi-
ate restoration of tissue structure and function. Mechanistically,
efferocytosis resembles stimulated macropinocytosis and is mor-
phologically distinct from classic forms of phagocytosis (Ogden
et al., 2001; Henson and Bratton, 2009). Due to differences in
recognition mechanisms, engagement, and signaling pathways, it
is not surprising that environmental factors havedifferential effects
on the various forms of endocytosis (Gratchev et al., 2006; Feng
et al., 2011).
Apoptotic cell recognition and efferocytosis by macrophages
has a profound inﬂuence on resolution of inﬂammation, largely
through secretion of anti-inﬂammatory cytokines, such as TGF-β
and IL-10 that inhibit inﬂammatory mediator production (Voll
et al., 1997; Fadok et al., 1998). Thus, macrophages responding
to PS on apoptotic cells have been shown to accelerate resolution
of LPS-induced lung inﬂammation in a TGF-β dependent man-
ner (Huynh et al., 2002), and infusion of PS liposomes attenuated
inﬂammation in murine skin edema and myocardial infarction
models (Ramos et al., 2007; Harel-Adar et al., 2011). Additionally,
local injection of PS liposomes decreased the amplitude of a CD4+
T cell response (Hoffmann et al., 2005) indicating that apoptotic
cell signaling can modulate adaptive immune responses. Finally,
efferocytosis of dying cells prevents their deterioration and release
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Table 1 | Phosphatidylserine, bridge molecules, and receptors for
apoptotic cells including those known to be modulated by nuclear
receptor signaling.
Ligand on
apoptotic cell
Bridge molecules Efferocytic receptor
PS None BAI1
PS None TIM1, TIM3, TIM4
PS None Stabilin-1, stabilin-2
PS None Receptor for advanced gly-
cation end products (RAGE)
PS; oxidized PS C1q*,**, MBL Calreticulin/LRP (CD91)*
PS; oxidized PS Gas6**, protein S Mer*,**,∧, Axl*,**, Tyro3
PS; oxidized PS MFG-E8*,** αVβ3/5 integrins
Thrombospondin** CD36*
PS; oxidized PS Collectins (SP-A, SP-D) LRP (CD91)*
Ligands, bridge molecules, and receptors are more comprehensively discussed
in reference (Henson and Bratton, 2009) and references therein.
*Expression regulated by PPAR-γ (Berry et al., 2007; Majai et al., 2007; Roszer
et al., 2011).
**Expression regulated by PPAR-δ (Mukundan et al., 2009).
∧Expression regulated by LXR (A-Gonzalez et al., 2009).
of phlogistic intracellular contents that can contribute to inﬂam-
mation and autoimmunity. Given the impact of efferocytosis on
suppression of inﬂammation, restoration of tissue homeostasis,
and shaping the immune response, this reviewwill focus on factors
in the tissue environment thatmodulate the ability ofmacrophages
to carry out these functions.
SECTION 1: MACROPHAGE PROGRAMMING AND
MODULATION OF EFFEROCYTOSIS
The increasingly complex list of so-called macrophage “pheno-
types” have been comprehensively reviewed elsewhere (Benoit
et al., 2008; Mosser and Zhang, 2008; Martinez et al., 2009) The
concept of phenotypes, while useful, is oversimpliﬁed, because
macrophages exhibit substantial plasticity,withmarkers and func-
tions readily altered by external signals (Gratchev et al., 2006;
Fernandez-Boyanapalli et al., 2009). Accordingly, we argue that it
is important to address the functional attributes of macrophages
under study or discussion, leading us to focus, here, on those asso-
ciated with differential capacity for efferocytosis. In general terms,
“classically activated” or M1 macrophages demonstrate dimin-
ished efferocytosis, increased phagocytosis of foreign organisms,
and enhanced production of pro-inﬂammatory cytokines, reac-
tive oxygen species (ROS), and nitric oxide (NO; Benoit et al.,
2008; Figure 1). This M1 programming state results from stimu-
lation with LPS and the innate cytokine IFNγ, or can be elicited by
IFNα/β-inducing TLR agonists (Mosser and Zhang, 2008), lead-
ing to inhibition of efferocytosis in part through TNFα and/or
oxidant-mediated mechanisms (McPhillips et al., 2007; Mich-
lewska et al., 2009). Because M1 macrophages are also associated
with Th1 T cell polarization, they exhibit protection against bacte-
rial infection. Such macrophages are evident early in the course
of infection or injury, e.g., peritonitis (Fernandez-Boyanapalli
et al., 2010a) and are designated in this review as inﬂammatory,
“efferocytic-low”macrophages.
On theopposite endof the spectrum,various“alternatively acti-
vated”orM2macrophages can be elicited by IL-4 and IL-13 (M2a),
a combination of TLR agonists and immune complexes (M2b),
glucocorticoids and IL-10 (M2c), M-CSF, or TGF-β (Xu et al.,
2006; Benoit et al., 2008; Mosser and Zhang, 2008; Martinez et al.,
2009). Collectively, these macrophages exhibit increased expres-
sion and/or activity of the nuclear receptors, PPARγ and PPARδ,
essential to their acquisition of “alternative activation” (Bouhlel
et al., 2007; Odegaard et al., 2007). They often display increased
levels of arginase, certain receptors (e.g., themacrophagemannose
receptor) and anti-inﬂammatory cytokines, whereas production
of pro-inﬂammatory cytokines, RNS, and ROS are downregu-
lated (Benoit et al., 2008; Olefsky and Glass, 2010; Figure 1). The
majority of these “alternative activation” states have been asso-
ciated with enhanced efferocytosis of apoptotic cells (and likely
also necrotic cells and cellular debris) supporting a role in res-
olution of inﬂammation. As such, these macrophages are seen
later during the resolution phase of inﬂammation, and hence-
forth,are called pro-resolving,or“efferocytic-high”(Bystromet al.,
2008; Fernandez-Boyanapalli et al., 2010a; Schif-Zuck et al., 2011).
Whether the in vivo shift from inﬂammatory to pro-resolving
state is attributable to recruitment, or expansion of different
macrophage populations within the milieu at differing stages of
inﬂammation (Jenkins et al., 2011), or rather represents given
macrophages responding to the changing milieu with a switch in
programming (Bystrom et al., 2008), or a combination, remains
an important, and largely unanswered question for most inﬂam-
matory processes. Importantly, two additional caveats deserve
mention: (i) much of the literature is based on programming of
murine macrophages which likely differs from human, and (ii)
cultured macrophages (e.g., M-CSF-treated human monocyte-
derived macrophages or murine bone marrow macrophages)
are programmed during culture with substantial inﬂuences on
subsequent responses (Fernandez-Boyanapalli et al., 2009).
MACROPHAGE PROGRAMMING FOR ENHANCED EFFEROCYTOSIS AND
ANTI-INFLAMMATORY CONSEQUENCES
Of the pro-resolving programming states, those elicited by IL-4
and IL-13 are the most thoroughly studied in relation to enhanced
efferocytic capacity. IL-4 and IL-13 increase expression and activ-
ity of the nuclear receptor PPARγ via STAT6 (Welch et al., 2003;
Berry et al., 2007; Szanto et al., 2010). IL-4 also induces production
of potential PPARγ-activating ligands, 13-HODE and15-HETE
through15-lipoxygenase activity (Huang et al., 1999).Macrophage
PPARγ activation, in turn, has three consequences relevant to
this review: (i) “alternative activation” with increased efferocytic
surface receptors (Table 1) and secretion of the bridge molecule
adiponectin; (ii) enhanced efferocytic capability; and (iii) suppres-
sion of inﬂammation. For somemacrophage populations, IL-4/IL-
13-induced PPARγ signaling enhances efferocytosis speciﬁcally
(Fernandez-Boyanapalli et al., 2009), while in others, it non-
speciﬁcally enhances other phagocytic functions: e.g., uptake of
opsonized cells (Aronoff et al., 2004), parasitized RBCs (Serghides
and Kain, 2001), and yeast (Gales et al., 2010). An overall increase
in phagocytic ability, especially for fungal and parasitic pathogens,
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FIGURE 1 | Macrophage programming either in vitro or in vivo
determines efferocytic capacity. Left: Inﬂammatory macrophages,
e.g., generated by stimuli such as LPS+ IFNγ have heightened
bactericidal activity and production of pro-inﬂammatory mediators,
and are programmed poorly for efferocytosis. Right: Following
activation of the nuclear receptors, pro-resolving, or resolution-phase
macrophages are programmed for heightened efferocytosis, with increased
expression of receptors and bridge molecules required for the recognition of
apoptotic cells, and the production of anti-inﬂammatory cytokines. In vivo,
over the course of acute inﬂammation macrophage programming and
function transitions from that of inﬂammatory macrophages to
resolution-phase macrophages.
is likely associated with PPARγ-mediated upregulation of fun-
gal and parasitic recognition receptors and related to the role of
“alternatively activated” macrophages in immunity against Th2
response-inducing pathogens (Raes et al., 2005; Gales et al., 2010).
IL-4/IL-13 also enhanced macrophage PPARδ expression, and
expression and release of bridge molecules (Table 1), and acquisi-
tion of anti-inﬂammatory functions (Kang et al., 2008). Both these
PPARs are known to heterodimerize with other nuclear receptors
to exert these actions, and accordingly, roles for LXR and RXRα
in enhanced efferocytosis have been demonstrated (A-Gonzalez
et al., 2009; Mukundan et al., 2009; Rebe et al., 2009; Roszer et al.,
2011). Direct connections between IL-4/IL-13 and LXR and RXRα
are still to be determined.
IL-4 also increases expression of the efferocytic receptors,
stabilin-1 and stabilin-2, although connectionswith nuclear recep-
tor signaling have not been made (Park et al., 2009). Efferocytic
programming of macrophages by cytokines, such asM-CSF, IL-10,
and TGF-β, are described but less understood. Likewise, pathways
for the expression of other apoptotic cell receptors, and indeed the
differences in the repertoire of receptors utilized by macrophages
in different tissues/milieus is poorly deﬁned (Henson and Bratton,
2009).
An important and emerging concept is that macrophage recog-
nition of apoptotic cells themselves can reinforce signaling path-
ways that shift their programming toward enhanced efferocytic
ability in a feedforward manner (Figure 1): e.g., apoptotic cell-
induced PPARγ, PPARδ, and LXR activation results in enhanced
CD36 andMer expression and secretion of efferocytic bridgemol-
ecules (A-Gonzalez et al., 2009; Mukundan et al., 2009; Roszer
et al., 2011). One mechanism by which apoptotic cells enhance
efferocytic programming is through PS-dependent induction of
IL-4 signaling to upregulate PPARγ (Fernandez-Boyanapalli et al.,
2009). Autocrine stimulation by TGF-β produced in response
to apoptotic cell recognition may similarly enhance PPARγ
expression (Freire-de-Lima et al., 2006).
Suppression of inﬂammation also results from activation of
these signaling pathways. Stimulation of PPARγ, PPARδ, and
LXR, RXRα are associated with reduced production of pro-
inﬂammatory mediators (Ghisletti et al., 2007; Mukundan et al.,
2009; Roszer et al., 2011). For example, PPARγ and LXR associate
with the co-repressor complex NCoR inhibiting its removal from
transcriptional binding sites driven by inﬂammatory cytokines.
Sustained NCoR occupation inhibits NF-κB down-regulating
transcription of its target genes, e.g., TNFα and IL-1β (Pascual
et al., 2005; Ghisletti et al., 2007; Jennewein et al., 2008). Recog-
nition of apoptotic cells also down-regulates pro-inﬂammatory
mediators through PS-induced stimulation of TGF-β production
(Huynh et al., 2002; Freire-de-Lima et al., 2006). Observations
such as these reinforce the concept of plasticity in macrophage
programming during the course of an inﬂammatory response
with early induction of protective properties and later develop-
ment of restorative activities to promote resolution (Figure 1).
Though the focus here is the role of efferocytic macrophages in
the resolution of acute inﬂammation, it should also be noted
that “pro-resolving” macrophages ameliorate chronic inﬂamma-
tion (Wang et al., 2007; Gordon and Martinez, 2010). Alterna-
tively, depending on context, consequences of such program-
ming may be detrimental. For instance, sustained production of
TGFβ may lead to over-exuberant ﬁbrotic responses, and there
is increasing evidence that the cultivation of immunosuppressive
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tumor-associatedmacrophages promote the growth, invasion, and
immune evasion of tumors (Martinez et al., 2009; Sica, 2010).
While important, these downstream consequences are beyond the
scope of this review and the reader is directed to recent references
on the subject.
MECHANISMS BY WHICH INFLAMMATORY MACROPHAGE
PROGRAMMING DECREASES EFFEROCYTIC CAPACITY
In the other direction, suppression of efferocytosis, but not other
forms of phagocytosis, is likely mediated both by early acting
inhibitors (below) as well as inﬂammatory macrophage program-
ming (Michlewska et al., 2009; Feng et al., 2011). This suggests
effects on pathways that are unique to the recognition and uptake
of apoptotic cells. Evidence for programming-related suppres-
sion of efferocytosis stems from studies of macrophages stim-
ulated with LPS demonstrating decreased expression of PPARγ
(Welch et al., 2003), and decreased transcription and serum lev-
els of efferocytosis-associated bridgemolecules Gas6 andMFG-E8
(Komura et al., 2009; Feng et al., 2011). Likewise, LPS induces the
transcription factor IRF5, which suppresses expression of effero-
cytic receptors CD36 and CD14 along with“alternative activation”
markers as it up-regulates pro-inﬂammatory cytokine production
(Krausgruber et al., 2011). Thus, the balance between expression
of IRF5 and IRF4, the latter driven by IL-4, governs “alterna-
tive activation”marker expression (El Chartouni et al., 2010) and
likely plays a role in determining macrophage efferocytic capacity.
Interestingly, stimulation of macrophages with the other “classical
activation” stimulus IFNγ by itself enhances phagocytosis of both
apoptotic cells and IgGopsonized targets in aNO-dependentman-
ner involving Rac activation (Fernandez-Boyanapalli et al., 2010b)
suggesting further complexity in the regulation of efferocytosis.
SECTION 2: EARLY ACTING ENHANCERS AND INHIBITORS IN
THE INFLAMMATORY MILIEU THAT MODULATE
EFFEROCYTOSIS
In addition to macrophage programmingmodulators, the inﬂam-
matory milieu contains numerous serum and cell-derived factors
that have immediate (or near immediate) early effects on effero-
cytosis (Figure 2) separate from the slower and more prolonged
consequences of macrophage programming. Many of these early
acting effectors have been found to shift the balance betweenRhoA
activation (inhibitory) andRac 1 activation (enhancing; Figure 2).
EARLY ACTING INHIBITORS
Previous studies demonstrated that LPS-mediated suppression
of efferocytosis was TNFα dependent (Michlewska et al., 2009;
Feng et al., 2011) and that short-term exposure to TNFα inhib-
ited macrophage efferocytosis in an oxidant-dependent manner
involving RhoA activation (McPhillips et al., 2007; Moon et al.,
2010). Similarly, lysophosphatidic acid (LPA) inhibits efferocy-
tosis through activation of RhoA (Morimoto et al., 2006). Other
inhibitors of efferocytosis in the inﬂammatorymilieu act by block-
ing macrophage recognition of apoptotic cells. These include
high mobility group box protein 1 (HMGB1), soluble receptor
for advanced glycation end products (RAGE), and annexin A5.
HMGB1 binds variousmacrophage receptors: its binding to RAGE
blocks its recognition of PS, and binding to αV integrins blocks
interactions with the bridge molecule,MFG-E8 (Table 1; Banerjee
et al., 2010; Friggeri et al., 2010, 2011; He et al., 2011). HMGB1
binding to RAGE also reinforces an inﬂammatory macrophage
state by stimulating NF-κB and enhancing pro-inﬂammatory
cytokine production (Qin et al., 2009). Alternatively, masking of
PS on apoptotic cells also impairs efferocytosis: soluble RAGE
(He et al., 2011) and annexin A5 (unlike annexin A1, see below;
Kenis et al., 2006) blockmacrophage recognition of apoptotic cells
by this mechanism. Collectively, these signals downregulate effe-
rocytosis and are likely to reinforce properties of inﬂammatory
macrophages.
EARLY ACTING ENHANCERS
Early acting enhancers are deﬁned operationally as agents that
rapidly augment the capacity and/or the capability ofmacrophages
to engulf apoptotic cells, often by increasing Rac 1 activity
(Figure 2). Such factors are found on apoptotic cells and in the
milieu, and many are made and released by macrophages them-
selves. Most enhancers identiﬁed to date appear to be modiﬁed
lipids. A distinguishing feature is their inability to drive efferocy-
tosis on their own (Frasch et al., 2011), i.e., they act by enhancing
existing stimuli. By contrast, PS or oxidized PS (Table 1), termed
inducers, drive macrophages to take up even viable cells when
they are inserted into the target cell membrane (Fadok et al., 1992;
Greenberg et al., 2006).
A modiﬁed phosphatidylserine species, lysophosphatidylserine
(lyso-PS), is an early acting enhancer produced in activated and
apoptosing neutrophils through an NADPH-oxidase dependent
pathway. In sterile peritonitis, lyso-PS is localized to the neutrophil
surface with its accumulation peaking at a time immediately pre-
ceding rapid neutrophil clearance by macrophages (Frasch et al.,
2008). Lyso-PS acts through the macrophage G2A receptor stim-
ulating the production of prostaglandin E2 (PGE2) leading to
cAMP and PKA-dependent augmentation of Rac1 activity. While
it has previously been reported that PGE2 inhibits efferocytosis,
this effect appears to be concentration dependent; concentrations
less than or equal to 1 nM in fact enhance efferocytosis, whereas
concentrations greater than 10 nM are inhibitory (Rossi et al.,
1998; Frasch et al., 2011). Macrophage production of PGE2 fol-
lowing efferocytosis (Voll et al., 1997; Fadok et al., 1998) has been
demonstrated to impair anti-microbial functions of macrophages
(Aronoff et al., 2004; Medeiros et al., 2009), and whether this
PGE2 ultimately enhances or inhibits subsequent efferocytosis is
unknown and is likely to be context and concentration dependent.
Lipoxins are a class of pro-resolving eicosanoids derived from
arachidonic acid that are produced and released by macrophages
during the resolution phase of inﬂammation via lipoxygenase
enzymes (Serhan et al., 2008). Lipoxin A4 is reported to enhance
efferocytosis in vitro (Godson et al., 2000) and in vivo (Mitchell
et al., 2002) by acting through the macrophage ALX receptor
(ALXR), which is also utilized by the PS-recognizing bridge mol-
ecule, annexin A1 (Scannell et al., 2007; Maderna et al., 2010).
Several other pro-resolution lipids derived from essential omega-3
fatty acids,have also been identiﬁed, including resolvins,protectins
(PD1), and maresins, all of which enhance macrophage phagocy-
tosis of pathogens, particles, and apoptotic cells (Schwab et al.,
2007; Serhan et al., 2008). How these pro-resolving lipids enhance
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FIGURE 2 | Early acting inhibitors and enhancers influence
efferocytic capacity of macrophages. Rho/Rac balance is altered by
inhibitors (left) and enhancers (right). ROS, reactive oxygen species; AnxV,
annexin A5; other abbreviations are deﬁned in the text. It is likely that early
acting agents also contribute to longer-term macrophage programming as
illustrated in Figure 1.
efferocytosis, the mechanisms and precise receptors involved,
are not well understood. For instance, resolvin E1 (RvE1), but
not the related RvD1, exerts its effects in part via the chimerin
receptor, ChemR23. Importantly, decreased production of pro-
inﬂammatory cytokines, perhaps as a result of efferocytosis, have
been observed with these pro-resolving lipids (Schwab et al.,
2007). Interestingly, the transition towardproduction of these pro-
resolving lipids (lipoxins, resolvins, and protectins) is mediated
through PGE2 (Serhan et al., 2008).
In addition to the short-term inﬂuences of enhancers or
inhibitors, these factors are likely to have downstream con-
tributions in shaping subsequent macrophage programming.
For example, since apoptotic cell recognition and efferocytosis
enhances the macrophage programming transition from inﬂam-
matory to pro-resolving, inﬂuencing this initial process may
thwart this transition (inhibitors), or speed, reinforce, and/or sus-
tain it (enhancers). For example, PGE2 and subsequent cAMP
production appear to be pivotal to programming inﬂammatory
macrophages to a pro-resolving phenotype under some conditions
(Bystrom et al., 2008). As such, early signals, e.g., lyso-PS, PGE2,
and cAMP, and possibly the other pro-resolving lipids, may con-
tribute collaboratively to initiate the transition from inﬂammatory
macrophage to resolving macrophage by carefully orchestrated
signaling.
SECTION 3: CONSEQUENCES OF DECREASED
EFFEROCYTOSIS AND PROLONGED INFLAMMATORY
PROGRAMMING
Defective apoptotic cell clearance is associated with many autoim-
mune and chronic inﬂammatory disorders including SLE (Koh
et al., 2000; Gaipl et al., 2007), type I diabetes (Haskins et al.,
2003), chronic obstructive pulmonary disease (Hodge et al., 2008),
and cardiovascular disease (Li et al., 2009). Mechanistically, dis-
integration of uncleared late apoptotic cells releases toxic intra-
cellular contents that spur inﬂammation (e.g., HMGB1) and pro-
vide epitopes (e.g., nuclear DNA) for autoantibody production,
a hallmark of autoimmune disorders such as SLE (Ma et al.,
2010). As a consequence, the resulting increased production of
pro-inﬂammatory cytokines (e.g., TNFα and IFNα; Koh et al.,
2000; Haskins et al., 2003) prolongs inﬂammatory, efferocytic-
low macrophage programming. Similarly, polymorphisms result-
ing in over-expression of the M1-associated transcription factor
IRF5 are associated with many inﬂammatory diseases (Dideberg
et al., 2007; Dieguez-Gonzalez et al., 2008; Kristjansdottir et al.,
2008).
Ineffective apoptotic cell clearance, and enhanced inﬂamma-
tion are also demonstrated where there are defects in “alternative
activation”mechanisms. Mice with PPARγ deﬁcient macrophages
have impaired efferocytosis, decreased expression of efferocytic
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receptors including CD36 and Mer tyrosine kinase, increased
kidney inﬂammation, and autoantibody production (Roszer et al.,
2011). PPARδ and LXR-deﬁcient mice also develop systemic
autoimmune disease associated with defective clearance and
decreased efferocytic receptor/bridge molecule expression (A-
Gonzalez et al., 2009; Mukundan et al., 2009). In a murine model
of chronic granulomatous disease (CGD), which exhibits chronic
inﬂammation, and mild autoimmunity, macrophages main-
tain a “classically activated” phenotype, illustrated by enhanced
pro-inﬂammatory cytokine production, impaired efferocytosis,
and decreased expression of PPARγ, MMR, CD36, and CD14
(Fernandez-Boyanapalli et al., 2009, 2010a).
The above evidence suggests that defective efferocytosis
in autoimmune and chronic inﬂammatory conditions may
result from continual exaggerated inﬂammatory activation of
macrophages and/or ineffective induction of signals associated
with programming toward pro-resolving macrophages. As such,
further investigation of the mechanisms leading to impaired
macrophage efferocytosis in these conditions, and approaches
for its reversal, may lead to the development of more effective
therapeutic strategies.
SECTION 4: THERAPEUTIC STRATEGIES TO ENHANCE
EFFEROCYTOSIS AND REDUCE INFLAMMATION
CURRENTLY AVAILABLE THERAPEUTICS
Based on the experimental evidence, enhancement of macrophage
efferocytosis, either by early actingmediators or throughprogram-
ming changes, may have efﬁcacy in treating disorders linked to
chronic inﬂammation and aberrant macrophage function. Many
anti-inﬂammatory drugs utilized clinically likely stimulate apop-
totic cell uptake, though for the most part,mechanisms are poorly
understood. For example, glucocorticoids with protean effects on
inﬂammation also enhance efferocytosis (Rhen and Cidlowski,
2005). In this regard they appear to act through a number of
mechanisms: (i) induced expression of the phospholipid bind-
ing protein annexin A1 and its receptor ALXR, which also binds
lipoxin A4 (Maderna et al., 2005), (ii) enhanced signaling via
Mer and its ligand, protein S (McColl et al., 2009), (iii) altered
Rac/Rho balance (Giles et al., 2001), and (iv) PPARγ-induced
programming (Majai et al., 2007). Statins, cholesterol lowering
drugs, are used with increasing frequency to treat inﬂamma-
tory diseases also enhance phagocytosis of apoptotic cells. The
mode of action is likely complex, but may work in part by reduc-
ing prenylation and membrane association of inhibitory RhoA
(Morimoto et al., 2006), as well as by inducing programming-
related changes through activation of PPARγ (Yano et al., 2007).
Another class of anti-inﬂammatory agents known to enhance effe-
rocytosis is the macrolide group of antibiotics. These likely alter
macrophage programming as well as increase levels of bridgemol-
ecules in vivo to enhance uptake of apoptotic cells (Yamaryo et al.,
2003; Hodge et al., 2008). Many of these current treatments have
diverse targets, making it difﬁcult to determine the precise role of
enhanced efferocytosis in their anti-inﬂammatory effects. Further-
more, many have adverse side effects. Accordingly, novel therapies
that more closely mimic normal resolution processes or target re-
programming ofmacrophages to speciﬁcally enhance efferocytosis
are needed.
NOVEL THERAPEUTIC TARGETS TO ENHANCE EFFEROCYTOSIS
Potential new therapeutic targets include modulation of signaling
pathways and mediators involved in both early acting events and
subsequentmacrophage programming. Oxidant-mediated activa-
tion of RhoA and suppression of efferocytosis, may be amenable
to antioxidant treatment. In a LPS-induced lung injury model,
antioxidants reduced inﬂammation, and improved macrophage
efferocytosis by inhibiting RhoA activation (Moon et al., 2010).
Similarly, antioxidant treatment in autoimmune NOD mice
dampened pro-inﬂammatory cytokine production and repaired
the macrophage efferocytic defect (Haskins et al., 2003). Another
potential therapy to enhance efferocytosis could be via lipox-
ins, including the related aspirin triggered 15-epi-lipoxins (Spite
and Serhan, 2010) that signal through ALXR. Lipoxins as well as
resolvins and protectins have been shown to reduce inﬂammation
and tissue damage in a variety of rodent models (Serhan et al.,
2008). Whether, and to what degree, any of these effects are a
direct result of enhanced efferocytosis remains to be determined.
Given that nuclear receptor signaling is strongly associated
with enhanced efferocytosis and suppression of inﬂammation,
PPARγ, PPARδ, and LXR agonists are natural therapeutic targets
for inﬂammatory diseases. LXR agonists were shown to reverse
defective macrophage efferocytosis and reduce disease severity in
a murine model of SLE (A-Gonzalez et al., 2009). Additionally,
PPARγ agonists reduced neutrophil numbers in rodent models
of acute inﬂammation, COPD, and asthma (Belvisi and Hele,
2008; Fernandez-Boyanapalli et al., 2010a). PPARγ and PPARδ
activation were also shown to decrease inﬂammation and disease
severity in experimental autoimmune encephalomyelitis (EAE),
the murine model of multiple sclerosis (Feinstein et al., 2002;
Polak et al., 2005). Recently, a direct association between improved
efferocytosis and treatment efﬁcacy has been demonstrated: treat-
ment with a PPARγ agonist resolved prolonged zymosan-induced
inﬂammation in amousemodel of CGD,which correspondedwith
macrophage “alternative activation” enhanced efferocytosis, and
increased TGFβ and IL-10 production (Fernandez-Boyanapalli
et al., 2010a).
In vivo administration of apoptotic cells exploits their sig-
naling to alter inﬂammatory programming in inﬂamed tissues;
their stimulation of phagocytes shapes subsequent immune and
inﬂammatory responses (Jonson et al., 2008). This has been
especially successful in graft versus host disease where a shift
in Th1 to Th2 T cell responses was driven by macrophage-
dependent induction of tolerogenic dendritic cells (DC) and
regulatory T cells (Gorgun et al., 2002; Kleinclauss et al.,
2006). In EAE, infusion of autoantigen-expressing apoptotic cells
induced tolerance to self antigens and reduced disease progres-
sion in a manner-dependent on macrophage-mediated regu-
lation of DC efferocytosis (Miyake et al., 2007). The mecha-
nisms involved in apoptotic cell infusion-induced regulation of
inﬂammation and induction of tolerance are not well studied,
however, it is likely mediated in part through apoptotic cell-
induced alterations inmacrophage programming. Treatment with
PS liposomes, which simulate signaling by apoptotic cells, has
also been effective. In sterile inﬂammatory models, administra-
tion of PS liposomes led to macrophage re-programming from
pro-inﬂammatory to anti-inﬂammatory states. As consequences,
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efferocytosis was enhanced (Fernandez-Boyanapalli et al., 2009),
tissue swelling and pro-inﬂammatory cytokine production were
reduced (Ramos et al., 2007), and repair of infarct tissue was
enhanced (Harel-Adar et al., 2011). As a cautionary note, how-
ever, administration of both apoptotic cells and PS liposomes
into inﬂamed tissues, and likely to inﬂammatory macrophages,
can also contribute (at least transiently) to exacerbated inﬂam-
mation (Medan et al., 2002; Borges et al., 2009), and disabled
host defense against pathogens (Medeiros et al., 2009). These
observations underscore the need to better understand the sig-
naling pathways involved in therapeutic induction of macrophage
anti-inﬂammatory programming and enhancement of efferocytic
capacity.
CONCLUSION
Macrophages, through their phagocytic functions and produc-
tion of cytokines and mediators, profoundly shape the course
of inﬂammation. Interpreting cues from the environment, they
orchestrate early pro-inﬂammatory responses to pathogens and
tissue injury, and ultimately produce anti-inﬂammatory lipids
and cytokines for the active suppression of inﬂammation and
restoration of tissue homeostasis. Their recognition and removal
of apoptotic cells are crucial to these latter events, and a consid-
erable body of data supports that their dysregulation contributes
to diverse autoimmune and chronic disease states. An increasing
understanding of the normal resolution mechanisms, especially
those that modulate apoptotic cell clearance through the stimula-
tion and programming of macrophages will undoubtedly bring
new therapeutic strategies to the forefront and will allow for
the development of more effective targeted and/or combinatorial
treatments.
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